Revvity secures fda approval for improved automated latent tuberculosis test

Waltham, mass.--(business wire)--revvity, inc. (nyse: rvty), today announced that the u.s. food and drug administration (fda) has approved the auto-pure 2400 liquid handling platform with the t-spot™.tb test. initially launched outside the u.s. in 2024, this powerful combination allows laboratories to improve productivity while maintaining superior clinical performance in latent tuberculosis (tb) detection. this milestone marks a significant advancement in the fight against tb with a faster hig.
RVTY Ratings Summary
RVTY Quant Ranking